G01N 2333/91235
With a phosphate group as acceptor
Official title: with a phosphate group as acceptor (2.7.4)
G01N2333/91235 (With a phosphate group as acceptor) appears on 16 US grants and 20 published applications in this corpus.
Search patents in G01N- Granted patents
- 16
- Published applications
- 20
- Assignees
- 23
- Inventors
- 64
- Latest grant
- 30 Jul 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 3 |
| 2003 | 0 | 2 |
| 2004 | 1 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 2 | 0 |
| 2012 | 1 | 1 |
| 2013 | 1 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 1 | 1 |
| 2017 | 1 | 3 |
| 2018 | 1 | 1 |
| 2019 | 2 | 0 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 1 | 0 |
| 2025 | 0 | 2 |
By publication year.
Recent patents
- Anti-NME antibody and method of treating cancer or cancer metastasis30 Jul 2024US 12,049,514 B2Minerva Biotechnologies Corporation
- Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA13 Jun 2023US 11,674,184 B2Enhancedbio Inc.
- Method for evaluating mesenchymal stem cell activity, method for culturing mesenchymal stem cells, method for producing therapeutic agent for liver dysfunction, and therapeutic agent for liver dysfunction18 Aug 2020US 10,744,159 B2Shibuya Corporation
- Method for determining the survival prognosis of a patient suffering from pancreatic cancer5 Nov 2019US 10,465,250 B2Acobiom
- Kit and method for measuring the activity of deoxynucleoside kinase29 Jan 2019US 10,190,149 B2Biovica International AB
- Thymidine kinase as a marker for immune checkpoint inhibitor efficacy21 Aug 2025US 2025/0263775 A1
- Method for maintaining nanopore sequencing speed20 Mar 2025US 2025/0092452 A1Bgi Shenzhen
- Anti-nme antibody and method of treating cancer or cancer metastasis7 Sep 2023US 2023/0279141 A1Minerva Biotechnologies Corporation
- Biomarker composition for diagnosing radiation-resistant cancer or for predicting prognosis of radiation therapy containing pmvk as active ingredient28 Jan 2021US 2021/0025007 A1Enhancedbio Inc.
- Method for determining the survival prognosis of a patient suffering from pancreatic cancer19 Apr 2018US 2018/0105881 A1Acobiom
Most cited
By later US patents
- Fluorescent capture assay for kinase activity employing anti-phosphotyrosine antibodies as capture and detection agents24US 6,406,869 B1Pharmacopeia, Inc. · 2002
- Method for the in vitro diagnosis of stroke8US 8,486,652 B2Bio-Rad Innovations · 2013
- Anti-NME antibody and method of treating cancer or cancer metastasis3US 12,049,514 B2Minerva Biotechnologies Corporation · 2024
- Fluorescent capture assay for kinase activity employing an anti-phosphotyrosine antibody as both the capture agent and detecting agent3US 6,806,056 B2Pharmacopeia Drug Discovery, Inc. · 2004
- Cell assay, method and reagents2US 6,949,351 B1The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland · 2005